Incyte is developing a first-in-class, selective arginase inhibitor.*
Arginase is an enzyme produced by immunosuppressive myeloid cells that prevents activation of effector T cells and NK cells in tumors. Arginase exerts its immunosuppressive effect by depleting the amino acid arginine in the TiME, which subsequently prevents activation and proliferation of cytotoxic T cells and NK cells. Inhibition of arginase activity reverses this immunosuppressive block and helps restore T-cell function. In preclinical models, arginase inhibition has been shown to enhance antitumor immunity and inhibit tumor growth.
*In collaboration with Calithera BioSciences, Inc.